Therefore, the immunohistochemical status of RB1 and p53 as well as that of RB1CC1 should be good predictors of the proliferative activity; thus, the RB1CC1-RB1 pathway demonstrated in our experiments could play a significant role in the progression of clinical breast cancer. Here, RB1CC1 is linked to breast cancer.